DRUG DISCOVERY 15 - ELRIG Bedside to Bench Target Identification and Target Engagement: Applications

  • View

  • Download

Embed Size (px)

Text of DRUG DISCOVERY 15 - ELRIG Bedside to Bench Target Identification and Target Engagement: Applications


    2ND - 3RD SEPTEMBER 2015



    European Laboratory Research & Innovation Group



    We are delighted to welcome you to the 9th annual ELRIG Drug Discovery conference, Drug Discovery 2015 at to our new Telford venue. I hope you will enjoy the excellent conferencing and networking facilities of this venue. We look forward to meeting with you over coffee or beer during the event to get your views on venue, themes, and key issues affecting drug discovery that we can bring into the programme for future years. This Telford & ironbridge region has an amazing heritage of applied innovation - do try to take in the World Heritage Site attractions while you are in the area.

    Both myself (Peter & Del) have previously been Drug Discovery conference directors in 2013 and 2014 and we are delighted to welcome Roberto, a great addition to the team for this year; and to acknowledge the great work of Liz Quinn as ELRIG Scientific Program Director in keeping things on track.

    The ELRIG Drug Discovery 2015 programme contains a remarkable series of presentations from leading scientists across Europe and beyond, covering advances in basic and translational aspects of drug discovery. The scientific sessions will as usual cover core themes within drug discovery:

    Innovation in Assay Development & Screening Chemistry Innovation in Lead Discovery Target Identification & Validation Phenotypic Discovery & Cell Imaging Oncology Drug Targets New Biologic Drugs & Technologies

    We are also delighted to introduce two new science sessions this year, firstly a new track on advances in Metabolic and Cardiovascular diseases, which are critical areas for public health around the world. And for the first time we have introduced a track covering the rapidly developing field of Cell & Gene Therapies.

    We want to acknowledge the great work of the session chairs in putting together the speaker programmes for these sessions - they have outdone themselves this year with an internationally renowned line-up.We have had some great plenary speakers in recent years, and we are delighted that this year we have secured David Thomas from Montreal, a world-renowned expert in protein trafficking disorders; and Tracy Hussell, head of the unique Manchester Collaborative Centre for Inflammation Research which brings major Pharma and academic experts together to address inflammatory diseases.

    Another exciting part of Drug Discovery conference iare the Technology Forums. These were a great success last year, and will again provide a more informal, interactive environment for you to discuss key issues and future directions in workshop-style events coordinated by leaders in the fields. These will address Anti-Infectives; the future of HTS; Enzymology; and Protein-Protein Interactions. Go along and join the discussions!

    ELRIG Drug Discovery 2015 will include a high quality scientific poster session, great networking opportunities, and an extensive vendor exhibition - please do quiz the poster presenters, and visit the exhibition to see the range of new products and innovations on display. Don't miss the Innovation Zone, for new and exciting emerging companies and technologies. We are also partnering with the SLAS to bring you a SLAS Author Workshop - a great way to improve your publication skills.

    Each year, the ELRIG Drug Discovery conference provides a fantastic communication and learning opportunity for scientists engaged in research fields across drug discovery, bringing together Academia, Biotech, Vendors, & Pharma, into a strong single community of scientists. It is now well established as the leading annual drug discovery event held in the UK. For those of you who have been before, we are glad to see you again; for those of you experiencing DD for the first time - we hope you learn, and have fun, here in Telford.


    Peter Simpson Del Tresize Roberto Solari



    There is no magic bullet, but there are important tips that every prospective author should know before submitting a scientific manuscript for consideration by a peer-reviewed journal. Julio Martin Plaza, PhD, of GlaxoSmithKline in Tres Cantos, Spain (and member of the Journal of Biomolecular Screening Editorial Board) will share step-by-step advice on how to design and write scientific research papers more clearly and effectively to improve their chances for successful publication. Attendees will learn what editors want, what they don't want, and how reviewers evaluate manuscripts.

    Wednesday September 2nd Room: Jackfield

    Protein trafficking diseases are defined by mutant proteins, that are destined for location at the plasma membrane, but are recognized as misfolded by the cellular protein quality control systems, retained in the endoplasmic reticulum (ER), retrotranslocated into the cytoplasm where it is degraded by the proteasome. Some mutants of secretory proteins are in fact functional if they can be induced to traffic to the cell surface. One example is the F508del-CFTR mutant that, when homzygous, causes most of the cases of cystic fibrosis. Screens for correctors of trafficking of F508del-CFTR have identified molecules that allow its correct cellular trafficking. These correctors fall into two general categories. The first are

    “pharmacological chaperones” that bind to the mutant F508del-CFTR molecule and promote its folding so that it escapes the quality control systems. The second are “proteostasis modulators” that act on the cellular quality control systems. While the first category of correctors are specific for the mutant F508del-CFTR molecule some of the second category of proteostasis modulators can correct the trafficking of mutant proteins of other protein trafficking diseases.

    Alveolar macrophages exist in a unique microenvironment and, despite historical evidence showing that they are in close contact with the respiratory epithelium, have until recently been investigated in isolation. The microenvironment of the airway lumen has a considerable influence on many aspects of alveolar macrophage phenotype, function and turnover. As the lungs adapt to environmental challenges, so too do alveolar macrophages adapt to accommodate the ever-changing needs of the tissue. I will discuss how working in an open innovation, pre-competitive environment with the UK’s largest pharmaceutical companies allows us to explore the unique characteristics of alveolar macrophages, the mechanisms that

    drive their adaptation and the direct and indirect influences of epithelial cells on them. I will also highlight how they adapt in the inflamed lung and the processes driving adaptation in a variety of inflammatory conditions. The unique tissue location and function of alveolar macrophages distinguish them from other macrophage populations. However, over-regulation of them in repair leads to bacterial exacerbations. Re-setting the inflammatory tone of the airspaces and particularly airway macrophages presents new therapeutic opportunities.

    Professor Tracy Hussell Director of the Manchester Collaborative Centre for Inflammation Research (MCCIR).

    The Development of New Therapeutics for respiratory inflammation Ironbridge room - 14.00 - Thursday 3rd September

    Dr. David Thomas CEO, Traffick Therapeutiques/Thérapeutiques, Inc

    Tackling Protein Trafficking Diseases Ironbridge room - 14.00 - Wednesday 2nd September


    Metabolic & Cardiovascular Drug Discovery Chemistry Innovation In Lead Discovery

    Target Identification & Validation Innovation In Assay Development & Screening

    Oncology Drug Targets Cell And Gene Therapy

    New Biological Drugs & Technologies Phenotypic Discovery & Cell Imaging

    Marcus Schindler AstraZeneca R&D Mölndal

    Paul Wyatt University of Dundee

    Michael Schneider Imperial College London

    Darren McKerrecher AstraZeneca

    Jon Moore Horizon Discovery

    Anne Phelan Pfizer Neusentis

    Hamish Ryder Cancer Research Technology

    Angela Gritti San Raffaele Telethon Institute

    for Gene Therapy (TIGET)

    Lutz Jermutus MedImmune

    Marc Bickle Max Planck Institute of

    Molecular Cell Biology & Genetics

    Rachel Grimley AstraZeneca

    Steve Hill University of Nottingham

    Herbie Newell Newcastle University

    Aniz Girach NightstaRx

    Katy Kettleborough MRC Technology

    Steve Ludbrook GlaxoSmithKline


    Plenary Keynote: Tackling Protein Trafficking Diseases

    Novel Inhibitors of MAP4K4 (HGK), an Acute Therapy to Prevent Cardiac Muscle Cell Death Following Myocardial


    Unravelling the Molecular Mechanisms of


    Nanotechnology, Imaging and Targeted Drug Therapy

    in Cardiac Pathology

    The Role of Post-Transcriptional

    Regulation in Cardiac Disease

    Myocyte Lipotoxicity: A Chemical Biology


    Synthetic Chemically Modified mRNA (modRNA): Towards A New Technology Platform for

    Cardiovascular Biology & Medicine

    Plenary Keynote: The Development of New Therapeutics for respiratory inflammation

    Design of Novel Building Blocks to Enhance Drug


    Phenotypic Drug Discovery: With A Lot of Help From Our


    Structure-Kinetic Relationshi